title: Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth.
abstract: A calcineurin-nuclear factor of activated T cells (NFAT) regulatory pathway has been implicated in the control of cardiac hypertrophy, suggesting one mechanism whereby alterations in intracellular calcium handling are linked to the expression of hypertrophy-associated genes. Although recent studies have demonstrated a necessary role for calcineurin as a mediator of cardiac hypertrophy, the potential involvement of NFAT transcription factors as downstream effectors of calcineurin signaling has not been evaluated. Accordingly, mice with targeted disruptions in NFATc3 and NFATc4 genes were characterized. Whereas the loss of NFATc4 did not compromise the ability of the myocardium to undergo hypertrophic growth, NFATc3-null mice demonstrated a significant reduction in calcineurin transgene-induced cardiac hypertrophy at 19 days, 26 days, 6 weeks, 8 weeks, and 10 weeks of age. NFATc3-null mice also demonstrated attenuated pressure overload- and angiotensin II-induced cardiac hypertrophy. These results provide genetic evidence that calcineurin-regulated responses require NFAT effectors in vivo.
authors.affiliation: Division of Molecular Cardiovascular Biology, Department of Pediatrics, Children's Hospital Medical Center, Cincinnati Ohio 45229-3039, USA.
authors.forename: Benjamin J
authors.initials: BJ
authors.lastname: Wilkins
authors.forename: Leon J
authors.initials: LJ
authors.lastname: De Windt
authors.forename: Orlando F
authors.initials: OF
authors.lastname: Bueno
authors.forename: Julian C
authors.initials: JC
authors.lastname: Braz
authors.forename: Betty J
authors.initials: BJ
authors.lastname: Glascock
authors.forename: Thomas F
authors.initials: TF
authors.lastname: Kimball
authors.forename: Jeffery D
authors.initials: JD
authors.lastname: Molkentin
mesh_terms: D000804:Angiotensin II / Q000378:metabolism; D000818:Animals; D015153:Blotting, Western; D019703:Calcineurin / Q000378:metabolism*; D002455:Cell Division; D002467:Cell Nucleus / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000235:genetics* / Q000502:physiology*; D005260:Female; D018390:Gene Targeting; D006984:Hypertrophy; D008297:Male; D051379:Mice; D008957:Models, Genetic; D016296:Mutagenesis; D016297:Mutagenesis, Site-Directed; D009206:Myocardium / Q000378:metabolism; D050778:NFATC Transcription Factors; D020033:Protein Isoforms; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D014157:Transcription Factors / Q000235:genetics* / Q000502:physiology*; D019076:Transgenes
chemical_list: D004268:DNA-Binding Proteins; D050778:NFATC Transcription Factors; C494009:Nfatc3 protein, mouse; C467907:Nfatc4 protein, mouse; D020033:Protein Isoforms; D012333:RNA, Messenger; D014157:Transcription Factors; C445503:transcription factor NF-AT c3; D000804:Angiotensin II; D019703:Calcineurin